Respiratory Syncytial Virus (RSV) Diagnostic Market Size is Expected to Grow at a CAGR of 11.20% from 2026 to 2035

According to Precedence Research, the global Respiratory Syncytial Virus (RSV) diagnostic market size was valued at USD 1.50 billion in 2025 and is predicted to reach around USD 4.34 billion by 2035, expanding at a CAGR of 11.20% from 2026 to 2035. This growth is primarily driven by an increasing prevalence of respiratory infections, a growing neonatal population, and the significant demand for in-vitro diagnostics along with point-of-care services.

The rapid advancement in diagnostic tools has greatly enhanced the speed and precision of RSV detection, positioning companies in this sector for promising opportunities.

Where Data Meets Strategic Clarity 📥 View Sample Pages of the Complete Report 👉 https://www.precedenceresearch.com/sample/8321

Respiratory Syncytial Virus (RSV) Diagnostic Market Size and Forecasts

• Market size in 2025: USD 1.50 Billion
• Market size in 2026: USD 1.67 Billion
• Market size by 2035: USD 4.34 Billion
• CAGR: 11.20% (2026-2035)
• Forecast period: 2026-2035
• Base year: 2025

How is Artificial Intelligence (AI) Transforming the RSV Diagnostic Market?

AI has started playing an integral role in transforming the way RSV diagnostics are performed. By utilizing algorithms to analyze trends in weather, hospital statistics, and epidemiological data, AI is allowing healthcare systems to predict RSV outbreaks before they fully manifest. Furthermore, AI enhances the interpretation of multiplex test results, helping differentiate between RSV, influenza, and COVID-19 infections. This has led to a more proactive diagnostic approach, assisting clinicians in making more informed decisions.

AI's ability to predict RSV outbreaks also contributes to better resource management in healthcare systems. Through AI-driven insights, testing volumes can be preemptively adjusted, improving efficiency and ensuring that diagnostic resources are deployed appropriately.

🔗 What's Fueling the Next Wave of Growth? 👉 https://www.precedenceresearch.com/respiratory-syncytial-virus-diagnostic-market

Respiratory Syncytial Virus (RSV) Diagnostic Market Growth Drivers

🔸 Elevated Incidence of Respiratory Infections: The increasing number of seasonal respiratory infections has heightened the demand for rapid, reliable diagnostic tools.

🔸 Increased Neonatal Population: Infants, especially those in neonatal care facilities, are highly susceptible to RSV, fueling the demand for targeted diagnostic solutions.

🔸 Technological Advancements in Diagnostics: The use of advanced diagnostic tools, especially molecular diagnostics, has made it easier to detect RSV faster and more accurately.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

Respiratory Syncytial Virus (RSV) Diagnostic Market Opportunities & Emerging Trends

🔸 AI-Driven Diagnostics: As predictive analytics evolve, AI will increasingly be used to forecast RSV outbreaks, transforming the diagnostic process from a reactive to a proactive one. This shift will allow for earlier detection and more timely interventions.

🔸 Integration with Data Networks: The growing trend of linking diagnostic data to computerized surveillance systems is enabling real-time monitoring of RSV trends. This integration provides healthcare professionals with immediate access to vital data, aiding in quicker decision-making.

🔸 Pediatric-Specific Diagnostic Innovation: Given the high incidence of RSV in infants, manufacturers are focusing on creating child-specific diagnostic solutions. These tools emphasize ease of use and quick turnaround times, which are critical in neonatal care settings.

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉 https://www.precedenceresearch.com/checkout/8321

Respiratory Syncytial Virus (RSV) Diagnostic Market Regional Analysis

North America held a 39.2% share in 2025, supported by strong surveillance systems and advanced molecular diagnostic adoption. The region's preparedness and technological integration reinforce its leadership position. The U.S. dominated within North America due to advanced laboratory infrastructure, multiplex PCR adoption, and strong reimbursement systems. This ensures consistent demand and technological leadership.

Asia-Pacific accounted for 22.5% of the market and is expected to grow the fastest. Growth is driven by improving healthcare infrastructure, rising awareness, and increased investment in molecular diagnostics across countries like China and India. China is expected to lead regional growth due to rapid healthcare modernization and rising investment in infectious disease monitoring. Expansion of domestic manufacturing is also reducing import dependence and strengthening local diagnostic capabilities.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy - Get the Sample Report@ https://www.precedenceresearch.com/sample/8321

Respiratory Syncytial Virus (RSV) Diagnostic Market Segment Analysis

🔸 Product & Service Analysis

The kits and assays segment led the RSV diagnostic market in 2025, driven by continuous demand for consumables used in every test. Their recurring usage, especially during seasonal RSV peaks, ensures steady revenue generation. Rapid antigen tests and molecular platforms heavily rely on these reagents, making them the most consistent revenue contributor in the market.

The software and services segment is expected to grow the fastest over the forecast period. Increasing reliance on real-time data, centralized reporting, and diagnostic analytics is transforming diagnostics into a connected ecosystem. These solutions are becoming essential for surveillance and decision-making, enhancing overall healthcare efficiency.

Diagnostic instruments and analyzers remain essential but are growing more gradually due to high upfront costs and longer replacement cycles. However, the shift toward automation and multiplex testing is steadily improving efficiency, accuracy, and throughput in laboratories.

🔸 Technology Analysis

Molecular diagnostics held the largest share of 55.0% in 2025, owing to its high sensitivity and ability to detect RSV along with other respiratory infections in multiplex panels. Despite higher costs, the industry increasingly favors accuracy-driven testing methods.

Rapid antigen detection tests held a 27.0% share, driven by their speed, affordability, and ease of use. They remain particularly important in point-of-care settings such as pediatrics and elderly care, where quick decisions are critical.

Immunoassays accounted for 12.0% of the market. While not the most advanced technology, they remain widely used in routine laboratory screening due to their reliability and established workflows.

🔸 End-User Analysis

Hospitals and clinics dominated with a 43.1% share in 2025, driven by high RSV case severity in infants and older adults. These facilities are central to rapid diagnosis and treatment decisions.

Diagnostic laboratories held a 31.5% share, supported by increasing outsourcing of complex testing and data management from healthcare providers. This ensures steady and scalable demand.

Point-of-care centers accounted for 18.2%, driven by the rising use of rapid CLIA-waived tests in urgent care and community clinics. Their key advantage is faster diagnosis closer to patients.

Home testing held a 7.2% share, constrained by regulatory challenges and accuracy concerns. However, it represents a growing future opportunity as decentralized healthcare expands.

Respiratory Syncytial Virus (RSV) Diagnostic Market Key Players

➢ Abbott Laboratories
➢ F. Hoffmann-La Roche Ltd.
➢ Becton, Dickinson and Company (BD)
➢ Danaher Corporation (Cepheid)
➢ bioMérieux SA
➢ Thermo Fisher Scientific Inc.
➢ QuidelOrtho Corporation
➢ Hologic, Inc.
➢ QIAGEN N.V.
➢ Siemens Healthineers A
➢ Bio-Rad Laboratories, Inc
➢ DiaSorin S.p.A.
➢ Sekisui Diagnostic
➢ Meridian Bioscience, Inc.
➢ Luminex Corporation

Latest Breakthroughs

⚡ In January 2026, GSK plc received extended approval for its RSV vaccine Arexvy, leading to an increased need for pre-vaccination screening and post-vaccination monitoring.

⚡ In June 2025, Merck & Co., Inc. launched Enflonsia (clesrovimab), a preventive antibody for infants, which further boosts the demand for accurate RSV diagnostics.

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

📥 Instant Report Delivery Available | 💳 Buy Now 👉 https://www.precedenceresearch.com/checkout/8321

Segments Covered in the Report

🔹 By Product & Service

Kits and Assays (Reagents)
Instruments/Analyzers
Software and Services

🔹 By Technology

Molecular Diagnostics (RT-PCR, NAAT)
Rapid Antigen Detection Tests (RADTs)
Immunoassays (ELISA, Chromatographic Immunoassays)
Direct Fluorescent Antibody (DFA)
Others (Viral Culture, Serology)

🔹 By End-User

Hospitals and Clinics
Diagnostic Laboratories
Point-of-Care (PoC) Testing Centers
Home Care/At-home Testing

🔹 By Region

North America
Latin America
Europe
Asia-pacific
Middle and East Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.